Arzerra Fourth Quarter and Full Year 2012 Net Sales Figures

Arzerra Fourth Quarter and Full Year 2012 Net Sales Figures

Company Announcement

  *Arzerra worldwide net sales in Q4 2012 totaled GBP 14.5 million
  *Full year 2012 Arzerra sales were GBP 60 million, an increase of 38% over
    2011
  *Genmab royalty income is DKK 27 million for Q4 2012 and DKK 111 million
    for the year

COPENHAGEN, Denmark; February 6, 2013 - Genmab A/S (Copenhagen:GEN) announced
today Arzerra(r) (ofatumumab) net sales during the fourth quarter of 2012 were
GBP 14.5 million (approx. DKK 133.2 million). This figure consists of net
sales in the U.S. of GBP 10.3 million and in the rest of the world GBP 4.2
million. Under the terms of the collaboration with GlaxoSmithKline (GSK),
Genmab expects to receive a royalty payment of approximately DKK 27 million.

Full year 2012 net sales of Arzerra totaled GBP 60 million (approx. DKK 552
million) worldwide, resulting in total royalty income to Genmab of
approximately DKK 111 million for the year.

The conversion from GBP to DKK has been made using the Danish Central Bank
average rates for the respective quarters in 2012.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra^(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^(r); the
Y-shaped Genmab logo^(r); HuMax^(r); HuMax-CD20^(r); DuoBody^(r), HexaBody^TM
and UniBody^(r). Arzerra^(r) is a trademark of GlaxoSmithKline.

Company Announcement no. 03
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
 
Press spacebar to pause and continue. Press esc to stop.